Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.53 |
| ▸ | HPGD | P15428 | 4/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 2/20 | 0.52 |
| ▸ | GLA | P06280 | 1/20 | 0.52 |
| ▸ | CA12 | O43570 | 5/20 | 0.50 |
| ▸ | CA9 | Q16790 | 5/20 | 0.50 |
| ▸ | CA1 | P00915 | 3/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.48 |
| ▸ | RAB9A | P51151 | 3/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | CASP3 | P42574 | 1/20 | 0.41 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.41 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.41 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29445883 | 1.00 | KDM4E (0.53) | KDM4EALDH1A1HPGDHSD17B10KMT2A | |
| SCHEMBL30828778 | 0.95 | KDM4E (0.50) | KDM4EALDH1A1HPGDHSD17B10KMT2A | |
| SCHEMBL3319962 | 0.94 | KDM4E (0.49) | KDM4EALDH1A1HPGDHSD17B10KMT2A | |
| SCHEMBL29470083 | 0.92 | KDM4E (0.52) | KDM4EALDH1A1HPGDHSD17B10KMT2A | |
| SCHEMBL3321274 | 0.91 | KDM4E (0.51) | KDM4EALDH1A1HPGDHSD17B10KMT2A | |
| SCHEMBL29987184 | 0.91 | KDM4E (0.52) | KDM4EALDH1A1HPGDHSD17B10KMT2A | |
| SCHEMBL29569923 | 0.91 | KDM4E (0.49) | KDM4EALDH1A1HPGDHSD17B10KMT2A | |
| SCHEMBL29396633 | 0.90 | KDM4E (0.41) | KDM4EALDH1A1HPGDHSD17B10KMT2A | |
| SCHEMBL1180114 | 0.89 | MAP2K1 (0.53) | KDM4EALDH1A1HPGDHSD17B10KMT2A | |
| SCHEMBL29850978 | 0.88 | KDM4E (0.48) | KDM4EALDH1A1HPGDHSD17B10KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 158 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2004018414-A2 | ANTIBACTERIAL AGENTS | PHARMACIA & UPJOHN COMPANY LLC (US) | 2004-03-04 | — | — | WO | claimed |
| US-20030219841-A1 | Method and reagent for the detection of apoptotic cells and of a protease activated during apoptosis | FERTIG GEORG (DE) | 2003-11-27 | — | — | US | claimed |
| EP-3720480-B1 | PHENOTYPIC MARKERS FOR CELL THERAPY AND RELATED METHODS | JUNO THERAPEUTICS INC (US) | 2026-05-27 | — | — | EP | disclosed |
| US-12636299-B2 | Terpenoid derivatives, pharmaceutical preparations containing these derivatives and their use in neuroprotection | UNIVERZITA PALACKEHO V OLOMOUCI (CZ) | 2026-05-26 | — | — | US | disclosed |
| US-12599593-B2 | Methods and compositions for treating non-ERK MAPK pathway inhibitor-resistant cancers | BIOMED VALLEY DISCOVERIES, INC. (US) | 2026-04-14 | — | — | US | disclosed |
| US-12595288-B2 | Vasopressin-2 receptor antagonist peptides and uses thereof | COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (FR) | 2026-04-07 | — | — | US | disclosed |
| WO-2026044087-A1 | INCREASED CELLULAR STABILITY FOR AAV PRODUCTION | SHAPE THERAPEUTICS INC. (US) | 2026-02-26 | — | — | WO | disclosed |
| US-12545674-B2 | Crystal of trifluoromethyl/chloro disubstituted sulfonamide selective BCL-2 inhibitor | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2026-02-10 | — | — | US | disclosed |
| US-12503437-B2 | 1,1-dimethyl-2-[(E)-2-phenylethenyl]-1H-benzo[e]indole derivatives and uses thereof | KAUNAS UNIVERSITY OF TECHNOLOGY (LT) | 2025-12-23 | — | — | US | disclosed |
| EP-4653055-A2 | METHODS AND COMPOSITIONS FOR TREATING NON-ERK MAPK PATHWAY INHIBITOR-RESISTANT CANCERS | Biomed Valley Discoveries, Inc. (US) | 2025-11-26 | — | — | EP | disclosed |
| EP-3946437-B1 | EX VIVO METHODS FOR PRODUCING A T CELL THERAPEUTIC AND RELATED COMPOSITIONS AND METHODS | H LEE MOFFITT CANCER CT & RES (US) | 2025-11-19 | — | — | EP | disclosed |
| US-20020012945-A1 | METHOD AND REAGENT FOR THE DETECTION OF APOPTOTIC CELLS AND OF A PROTEASE ACTIVATED DURING APOPTOSIS | ROCHE DIAGNOSTICS GMBH (DE) | 2002-01-31 | — | — | US | disclosed |
| EP-0988035-A4 | CASPASES AND APOPTOSIS | SMITHKLINE BECKMAN CORP (US) | 2001-09-19 | — | — | EP | disclosed |
| US-6214858-B1 | PREVENTING AND TREATING EXCESSIVE CELL DEATH USING OXINDOLE DERIVATIVES | SMITHKLINE BEECHAM CORPORATION | 2001-04-10 | — | — | US | disclosed |
| WO-2001022966-A1 | CASPASES AND APOPTOSIS | SMITHKLINE BEECHAM CORPORATION (US) | 2001-04-05 | — | — | WO | disclosed |
| EP-1087663-A2 | CASPASES AND APOPTOSIS | SMITHKLINE BEECHAM CORPORATION (US) | 2001-04-04 | — | — | EP | disclosed |
| EP-0988035-A1 | CASPASES AND APOPTOSIS | SMITHKLINE BEECHAM CORPORATION (US) | 2000-03-29 | — | — | EP | disclosed |
| WO-1999065451-A2 | CASPASES AND APOPTOSIS | SMITHKLINE BEECHAM CORPORATION (US) | 1999-12-23 | — | — | WO | disclosed |
| EP-0955377-A1 | Method for the detection of apoptosis activated protease | Roche Diagnostics GmbH (DE) | 1999-11-10 | — | — | EP | disclosed |
| WO-1999006042-A1 | CASPASES AND APOPTOSIS | SMITHKLINE BEECHAM CORPORATION (US) | 1999-02-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12545674-B2 | Crystal of trifluoromethyl/chloro disubstituted sulfonamide selective BCL-2 inhibitor | BCL2L11, BCL2L1, BCL2L2 | KDM4E 2572/4885ALDH1A1 3517/4885HPGD 4325/4885 |
| US-12636299-B2 | Terpenoid derivatives, pharmaceutical preparations containing these derivatives and their use in neuroprotection | GALC, HK1, SNCA | KDM4E 4743/4885ALDH1A1 958/4885HPGD 289/4885 |
| US-12503437-B2 | 1,1-dimethyl-2-[(E)-2-phenylethenyl]-1H-benzo[e]indole derivatives and uses thereof | IDO1, IDO2, ALDH1B1 | KDM4E 814/4885ALDH1A1 7/4885HPGD 231/4885 |
| US-12595288-B2 | Vasopressin-2 receptor antagonist peptides and uses thereof | AVPR2, AVPR1A, AVPR1B | KDM4E 1291/4885ALDH1A1 4852/4885HPGD 2539/4885 |
| US-12599593-B2 | Methods and compositions for treating non-ERK MAPK pathway inhibitor-resistant cancers | MOK, TTK, MAPK4 | KDM4E 1858/4885ALDH1A1 4404/4885HPGD 2525/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.